secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2021-10-28T23:59:59+00:00
Accession:  0001493152-21-026649
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.01, 9.01, 3.02, 4.01, 5.03, 5.01, 5.02, 5.06
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics completes de-SPAC merger; OLD SAB valued at $300M
---------------------------------------------------------------------

- OLD SAB equity value set at $300M; conversion rate $10.10 per share.
- Holders of 8,030,289 BCYP shares redeemed for ~$81.1M at ~$10.10/share.
- Approximately $21.9M released to Company upon closing; $13.1M escrowed with Radcliffe.
- Post-merger shares outstanding: 43,474,779; additional 12M earnout shares tied to stock price milestones.
- Board set at 7 members; CFO Russell Beyer gets new employment agreement ($300K base, stock options).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000149315221026649/0001493152-21-026649-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000149315221026649/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-026649

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer